{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Period+C&page=28",
    "query": {
      "intervention": "Period C",
      "page": 28
    },
    "page_size": 10
  },
  "pagination": {
    "page": 28,
    "page_size": 10,
    "total_count": 882,
    "total_pages": 89,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Period+C&page=29&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Period+C&page=27&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T12:32:40.357Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05210699",
      "title": "CSD201201: Study to Assess Elements of Abuse Liability for Electronic Nicotine Delivery System P12",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Smoking",
        "Smoking Behaviors",
        "Tobacco Use",
        "Tobacco Smoking"
      ],
      "interventions": [
        {
          "name": "Product A",
          "type": "OTHER"
        },
        {
          "name": "Product B",
          "type": "OTHER"
        },
        {
          "name": "Product C",
          "type": "OTHER"
        },
        {
          "name": "Product D",
          "type": "OTHER"
        },
        {
          "name": "Product E",
          "type": "OTHER"
        },
        {
          "name": "Product N",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "RAI Services Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "21 Years to 60 Years"
      },
      "enrollment_count": 36,
      "start_date": "2022-03-21",
      "completion_date": "2022-05-17",
      "has_results": false,
      "last_update_posted_date": "2022-06-29",
      "last_synced_at": "2026-10-31T12:32:40.357Z",
      "location_count": 2,
      "location_summary": "Springfield, Missouri • Knoxville, Tennessee",
      "locations": [
        {
          "city": "Springfield",
          "state": "Missouri"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05210699"
    },
    {
      "nct_id": "NCT02315326",
      "title": "Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL)",
        "Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)"
      ],
      "interventions": [
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "HD- Methotrexate (MTX)",
          "type": "DRUG"
        },
        {
          "name": "Rituximab + HD- Methotrexate (MTX)",
          "type": "DRUG"
        },
        {
          "name": "procarbazine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 93,
      "start_date": "2014-12-08",
      "completion_date": "2026-01-28",
      "has_results": false,
      "last_update_posted_date": "2026-02-02",
      "last_synced_at": "2026-10-31T12:32:40.357Z",
      "location_count": 7,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02315326"
    },
    {
      "nct_id": "NCT05127226",
      "title": "HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Angelman Syndrome"
      ],
      "interventions": [
        {
          "name": "ION582",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ionis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "0 Years to 50 Years"
      },
      "enrollment_count": 71,
      "start_date": "2021-12-22",
      "completion_date": "2029-03",
      "has_results": false,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-10-31T12:32:40.357Z",
      "location_count": 6,
      "location_summary": "San Diego, California • Aurora, Colorado • Chicago, Illinois + 3 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Carrboro",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05127226"
    },
    {
      "nct_id": "NCT04178096",
      "title": "Using Data-Driven Implementation Strategies to Improve the Quality of Cirrhosis Care",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cirrhosis, Liver"
      ],
      "interventions": [
        {
          "name": "Quality Improvement Intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2020-09-18",
      "completion_date": "2023-12-31",
      "has_results": true,
      "last_update_posted_date": "2025-04-01",
      "last_synced_at": "2026-10-31T12:32:40.357Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04178096"
    },
    {
      "nct_id": "NCT07222579",
      "title": "Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "CD19 Positive",
        "Mixed Phenotype Acute Leukemia (MPAL)"
      ],
      "interventions": [
        {
          "name": "Subcutaneous Blinatumomab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "West Virginia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2026-01-15",
      "completion_date": "2031-08",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-10-31T12:32:40.357Z",
      "location_count": 1,
      "location_summary": "Morgantown, West Virginia",
      "locations": [
        {
          "city": "Morgantown",
          "state": "West Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07222579"
    },
    {
      "nct_id": "NCT04867980",
      "title": "A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "ACP-196",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin 400 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Acerta Pharma BV",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 48,
      "start_date": "2016-04-01",
      "completion_date": "2016-05-09",
      "has_results": false,
      "last_update_posted_date": "2021-04-30",
      "last_synced_at": "2026-10-31T12:32:40.357Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04867980"
    },
    {
      "nct_id": "NCT04508179",
      "title": "A Phase 1 SAD and MAD Study of the Safety, Tolerability and PK of 7HP349 in Normal Healthy Male Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "7HP349 Single Ascending Dose",
          "type": "DRUG"
        },
        {
          "name": "7HP349 Multiple Ascending Dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo Single Ascending Dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo Multiple Ascending Dose",
          "type": "DRUG"
        },
        {
          "name": "7HP349 Food Effect",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "7 Hills Pharma, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "18 Years to 45 Years · Male only"
      },
      "enrollment_count": 60,
      "start_date": "2020-10-28",
      "completion_date": "2021-10-25",
      "has_results": false,
      "last_update_posted_date": "2021-11-02",
      "last_synced_at": "2026-10-31T12:32:40.357Z",
      "location_count": 1,
      "location_summary": "Secaucus, New Jersey",
      "locations": [
        {
          "city": "Secaucus",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04508179"
    },
    {
      "nct_id": "NCT07613359",
      "title": "A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Antibody-Mediated Rejection (AMR)"
      ],
      "interventions": [
        {
          "name": "Mezagitamab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 36,
      "start_date": "2026-10-15",
      "completion_date": "2029-01-15",
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-31T12:32:40.357Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • San Francisco, California • Miami, Florida + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07613359"
    },
    {
      "nct_id": "NCT05933187",
      "title": "A Study Evaluating the Pharmacokinetics and Relative Bioavailability of Emraclidine Immediate-Release Tablets in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "Treatment A: Emraclidine 30mg IR tablets (reference)",
          "type": "DRUG"
        },
        {
          "name": "Treatment B: Emraclidine 30mg IR test tablets 1",
          "type": "DRUG"
        },
        {
          "name": "Treatment C: Emraclidine 30mg IR test tablets 2",
          "type": "DRUG"
        },
        {
          "name": "Treatment D: Emraclidine 30mg IR test tablets 3",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cerevel Therapeutics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 15,
      "start_date": "2023-07-19",
      "completion_date": "2023-09-12",
      "has_results": false,
      "last_update_posted_date": "2023-11-24",
      "last_synced_at": "2026-10-31T12:32:40.357Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05933187"
    },
    {
      "nct_id": "NCT06692764",
      "title": "A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atherosclerotic Cardiovascular Disease"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "AZD0780",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 202,
      "start_date": "2024-10-30",
      "completion_date": "2025-05-02",
      "has_results": false,
      "last_update_posted_date": "2026-02-18",
      "last_synced_at": "2026-10-31T12:32:40.357Z",
      "location_count": 26,
      "location_summary": "Inglewood, California • Northridge, California • Pomona, California + 20 more",
      "locations": [
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Pomona",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06692764"
    }
  ]
}